Results for “ ”

Entry Author Date Location
Codiak Bio’s IPO Brings In $82M as Exosome Clinical Trials Begin 10/14/20 Boston
Despite Phase 2 Failure, Gossamer Bio Sees a Path for Drug in Asthma 10/13/20 San Diego
SQZ Biotech Lines Up an IPO on the NYSE to Fund Cell Therapy R&D 10/12/20 Boston
“Opioid Stacking” Concerns Lead FDA to Reject Avenue Therapeutics Drug 10/12/20 New York
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More 10/09/20 National
BIO Launches ‘Biotech Votes’ Campaign to Encourage Registration and Informed Voting 10/08/20 Boston
Bristol Myers to Buy MyoKardia, FDA-Ready Heart Disease Drug for $13.1B 10/05/20 New York
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More 10/02/20 National
FDA Lifts Solid Bio Clinical Hold, Duchenne Study Cleared to Resume 10/01/20 Boston
Pfizer Pumps $200M Into CStone for Rights to PD-L1 Cancer Drug in China 09/30/20 New York
With Phase 2 Data in Hand, Ovid Eyes Multiple Pivotal Trials for Epilepsy Drug 09/30/20 New York
Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs 09/28/20 Boston
Bio Roundup: Grail Acquisition, Libra’s Launch, Tau Trial Results & More 09/25/20 National
Monte Rosa Raises $96M for “Glue-Based” Protein Degrading Drugs 09/24/20 Boston
Xconomy Awards On-Demand ‘Meet the Finalists’ Webcast Series Continues This Week 09/21/20 Boston
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More 09/18/20 National
Moderna CMO Talks COVID-19 Vaccine at the Xcelerate Keynote Series 09/16/20 Boston
Neogene Therapeutics Grabs $110M to Tackle Solid Tumors With Cell Therapy 09/15/20 Europe
Seattle Genetics Lands $1.72B From Merck in Pair of Cancer Drug Deals 09/14/20 Seattle
Gilead Adds “Cornerstone” Cancer Drug in $21B Immunomedics Buyout 09/14/20 San Francisco
Join Xconomy Next Week at the Virtual Xcelerate Keynote Series at Biotech Week Boston 09/14/20 Boston
Bio Roundup: COVID-19 Pact, Gavreto Approval, Generative Biology & More 09/11/20 National
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More 09/04/20 National
Reeling From FDA Rejection, Intercept Pharma Slashes Headcount by 25% 09/01/20 New York
Early Bird Sale for Xcelerate at Biotech Week Boston Ends This Friday 08/31/20 Boston
Biotech Roundup: FDA Culpa, Tricida Trips, Freenome’s Funding & More 08/28/20 National
Athira Aims for the Nasdaq to Advance Alzheimer’s Drug to Phase 2 Tests 08/27/20 Seattle
AbbVie & UroGen Overactive Bladder Treatment Misses in Phase 2 Trial 08/27/20 New York
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases 08/26/20 Boston
FDA Adds Plasma as 2nd COVID-19 Treatment Under Emergency Guidelines 08/24/20 National
Page 1 of 299 next page »